Version history

{
  "session_id": "sess_SDA-2026-04-04-gap-neuroinflammation-microglial-20260404_20260412-074848",
  "round_number": 3,
  "agent_persona": "persona-domain_expert",
  "agent_backend": "minimax/MiniMax-M2.7",
  "action": "support",
  "content": "\n\n# Domain Expert Evaluation: Microglial Priming Hypotheses\n\n---\n\n## Part I: Hypotheses with Highest Translational Potential\n\n### Hypothesis 1 (PRC2/EZH2 Epigenetic Lock-In) — Moderate-High Potential\n\nThe concept of stable pro-inflammatory microglial states amenable to therapeutic reversal has clear clinical logic. However, EZH2 itself is a challenging pharmacological target — broad EZH2 inhibition would affect all CNS cell types, and systemic EZH2 modulators carry oncological risk given EZH2's role as a tumor suppressor in certain contexts. The hypothesis is mechanistically attractive but requires an intervention that can selectively restore EZH2 function in microglia without disrupting other cell populations.\n\n### Hypothesis 2 (DAMPs/TREM2 Axis) — Highest Translational Potential\n\nThis is the most clinically tractable framing. TREM2 is one of the most compelling microglial-specific genetic risk factors for AD — rare variants (R47H, R62H) confer 2–4x increased AD risk (Guerreiro et al., NEJM 2013; Jonsson et al., PNAS 2013). Biologic agents targeting TREM2 are already in early clinical development (AL002, AL003 by Alector/AbbVie). The hypothesis has a defined patient population (carriers of TREM2 risk variants), an existing therapeutic modality, and measurable biomarkers (CSF sTREM2, CSF mTREM2).\n\n### Hypothesis 3 (NLRP3 Inflammasome/P2X7 Axis) — High Potential via Repurposing\n\nNLRP3 inhibitors (MCC950, newer derivatives) and P2X7 antagonists are in clinical development for systemic inflammatory conditions (e.g., inflammatory bowel disease, rheumatoid arthritis). Several are blood-brain barrier permeable. This creates an immediate opportunity for drug repurposing with established safety profiles. The hypothesis is mechanistically connected to the other arms — DAMPs (HMGB1, ATP, aggregated proteins) trigger NLRP3 via P2X7, and NLRP3 activation produces mature IL-1β and IL-18 that drive priming. This axis integrates the cytokine, DAMP, and metabolic components of the overarching framework.\n\n---\n\n## Part II:",
  "tokens_used": "510"
}